NEW YORK (GenomeWeb) – Precision for Medicine announced today that it has acquired German specialty lab Epiontis, which provides epigenetic immune cell assays for clinical trial immune monitoring.
Epiontis' assays are based on a proprietary PCR-based technology that amplifies and detects euchromatic DNA expressed exclusively by cell types of interest. The company — which said it services 17 of the top 20 global pharmaceutical firms — offers assays for cells including regulatory T cells, CD4 cells, monocytes, and neutrophil granulocytes, and performs all measurements in-house.
"The acquisition of Epiontis allows Precision to significantly expand upon our immune monitoring capabilities, and their technology provides a faster, economically viable, and easier global solution for immune monitoring under a variety of scenarios," Precision for Medicine President Chad Clark said in a statement. "In addition, having recently opened Precision offices in Paris and Edinburgh, Epiontis' Berlin operation provides us an additional operational base for Europe as we continue our international expansion."
Specific terms of the deal were not disclosed.
Last month, Precision for Medicine acquired Agility Clinical, a contract research organization focused on clinical development of rare diseases and orphan therapies, and earlier in the year it acquired custom cell-based and immunoassay product developer Applied Immunology. In early 2016, the firm agreed to buy oncology-focused contract research organization ACT Oncology.